Description du projet
Améliorer le traitement des troubles mentaux
Les troubles mentaux représentent l’un fardeaux les plus lourds pour le système de santé européen, sachant qu’un grand nombre de patients ne disposent pas d’options de traitement efficaces. Les traitements actuels reposent sur une approche par tâtonnements; comme les multimorbidités sont fréquentes, cela débouche souvent sur de la polypharmacie et de mauvais résultats. Le projet REALMENT, financé par l’UE, cherche à optimiser le traitement des troubles mentaux grâce à de nouvelles stratégies de médecine de précision basées sur les options pharmaceutiques actuelles. Grâce aux efforts déployés dans le cadre du projet, les meilleurs instituts de recherche mondiaux et l’industrie pharmaceutique se retrouveront à la pointe de la recherche sur les troubles mentaux.
Objectif
Mental disorders represent one of the largest burdens for the European Health Care system, due to large number of patients and a lack of efficient treatment options. Today, drug treatment of mental disorders is characterized by severe adverse effects and suboptimal response in more than a third of the patients. Optimizing treatment is based on a trial-and-error approach, which combined with frequent multi-morbidities, often leads to polypharmacy and poor outcome. Due to limited understanding of the disease mechanisms that underlie mental disorders, new drugs with novel therapeutic targets are lacking, and existing treatments are ineffective for many people. It is therefore urgent that cutting-edge research approaches are deployed to develop innovative tools to individualize treatments using available psychiatric medication, and thus improve clinical outcomes and reduce costs for health care systems. The main goal of the multidisciplinary REALMENT project is to optimize treatment of mental disorders through novel precision medicine strategies based on current pharmaceutical options. REALMENT includes world leading research institutes and pharmaceutical industry at the very forefront of mental disorder research. REALMENT will achieve its objectives by exploiting population-scale Real-World Data (RWD) in combination with Randomized Clinical Trial (RCT) data available to the partners. Big data from populations (Nordic registries), cohorts (European biobanks), and eHealth samples (medical records), including whole genome genotypes (n=1.9 million), will be analysed in an EU-wide sustainable infrastructure using artificial intelligence and machine learning to develop prediction and stratification tools (precision psychiatry). These algorithms will be validated in large RCT data (n=10k) and re-phenotyping projects, and implemented in a clinical management platform (4MENT), which will be made available to provide decision support to clinicians to optimize therapeutic effects.
Champ scientifique
- medical and health scienceshealth scienceshealth care serviceseHealth
- medical and health sciencesclinical medicinepsychiatry
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencescomputer and information sciencesdata sciencebig data
- medical and health scienceshealth sciencespersonalized medicine
Mots‑clés
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
0313 Oslo
Norvège